Theriva Biologics, Inc. Common Stock (TOVX)
Frequently Asked Questions About Theriva Biologics, Inc. Common Stock (TOVX)
How can one invest in Theriva Biologics?
Investing in Theriva Biologics can be done through brokerage accounts that allow trading of NYSE stocks. Interested investors should conduct thorough research on the company, its financials, and market positions before making any investment decisions.
How does Theriva Biologics approach strategic partnerships?
Theriva Biologics actively seeks strategic partnerships with other biotech and pharmaceutical companies, research institutions, and organizations. These collaborations are essential for accelerating the development of their therapies, sharing knowledge, and expanding market opportunities.
How does Theriva Biologics intend to use its proprietary technology?
Theriva Biologics intends to use its proprietary technology platform to identify and develop new biologic candidates that can modulate the immune response while targeting disease mechanisms. This technology is integral to their strategy of creating therapies that can significantly improve patient outcomes.
Is Theriva Biologics publicly traded?
Yes, Theriva Biologics is a publicly traded company. Investors can buy and sell shares of the company through stock exchanges, which provides transparency and can help secure funding for clinical trials and development efforts.
What are some of the challenges faced by Theriva Biologics?
Theriva Biologics faces several challenges typical of the biotechnology industry, including navigating regulatory approvals, securing funding for research and development, and the inherent risks associated with clinical trials. Successfully overcoming these challenges is crucial for the company’s future growth and product commercialization.
What are the company's future goals?
Theriva Biologics aims to advance its therapeutic candidates through clinical trials and seek regulatory approvals to bring innovative treatments to market. The company is dedicated to expanding its pipeline and exploring new opportunities to address various diseases with high unmet medical needs.
What does Theriva Biologics, Inc. do?
Theriva Biologics, Inc. is a clinical-stage biotechnology company focused on developing innovative therapies for patients with serious diseases. The company specializes in leveraging unique technologies to create biologic therapeutics that aim to address significant unmet medical needs, particularly in the fields of oncology and infectious diseases.
What is the company’s strategy for drug development?
Theriva Biologics' strategy for drug development is centered on utilizing its proprietary technology platform to discover and validate new therapeutic candidates. This includes a focus on rigorous preclinical and clinical studies, ensuring that product development is grounded in solid scientific evidence.
What is the importance of the clinical trials for Theriva Biologics?
Clinical trials are critical for Theriva Biologics as they provide necessary data on the safety and efficacy of their therapeutics. Successful trials are essential for obtaining regulatory approvals and ultimately ensuring that their products can be offered to patients in need.
What is the ticker symbol for Theriva Biologics, Inc.?
The ticker symbol for Theriva Biologics, Inc. is TOVX. It is listed on the New York Stock Exchange (NYSE), enabling investors to trade shares of the company on the public market.
What is the vision of Theriva Biologics?
Theriva Biologics' vision is to transform the treatment landscape for patients suffering from serious diseases by developing innovative biologic therapies. The company is dedicated to addressing unmet medical needs through scientific excellence and collaboration in the biopharmaceutical space.
What is Theriva Biologics' lead product candidate?
Theriva Biologics' lead product candidate is TOVX-040, which is currently in clinical trials. This candidate aims to offer new treatment options for patients suffering from specific types of cancer, and it reflects the company's commitment to utilizing advanced science in therapeutic development.
What role do investors play in the success of Theriva Biologics?
Investors play a vital role in the success of Theriva Biologics by providing the necessary capital to fund research, clinical trials, and business operations. Their support can help accelerate the company’s development timelines and enable it to achieve its strategic goals.
What stage is Theriva Biologics in its clinical development?
Theriva Biologics is currently in the clinical development stage, advancing its product candidates through various phases of clinical trials. The progress is aimed at generating data to support safety and efficacy, ultimately leading to regulatory submission and potential commercialization.
What type of investors might be interested in Theriva Biologics?
Investors interested in Theriva Biologics might include institutional investors, venture capitalists, and individual investors who are focused on biotechnology and healthcare sectors. Those looking for growth opportunities in the clinical-stage biotech space may find Theriva appealing due to its innovative therapies and robust pipeline.
What types of therapies does Theriva Biologics focus on?
Theriva Biologics focuses on developing biologic therapies, particularly in the fields of oncology and infectious diseases. The company's pipeline includes innovative approaches to tackle diseases that currently have limited treatment options, utilizing its proprietary platform technology.
When was Theriva Biologics, Inc. founded?
Theriva Biologics, Inc. was founded in 2017. Since its inception, the company has focused on advancing its proprietary technologies and developing novel therapeutic candidates aimed at improving patient outcomes in serious medical conditions.
Where is Theriva Biologics headquartered?
Theriva Biologics is headquartered in Durham, North Carolina. This location is part of a thriving biotechnology community that allows the company to access necessary talent, research institutions, and potential collaborations.
Who are the key executives at Theriva Biologics?
The key executives at Theriva Biologics include a diverse team of professionals with extensive experience in biotechnology and pharmaceuticals. Their leadership encompasses areas such as drug development, regulatory affairs, and operational management, all of which are critical for the company's growth and success.
What is the current price of Theriva Biologics, Inc. Common Stock?
The current price of Theriva Biologics, Inc. Common Stock is 0.3820
When was Theriva Biologics, Inc. Common Stock last traded?
The last trade of Theriva Biologics, Inc. Common Stock was at 6:30 pm EDT on May 6th, 2026
What is the market capitalization of Theriva Biologics, Inc. Common Stock?
The market capitalization of Theriva Biologics, Inc. Common Stock is 1.06M
How many shares of Theriva Biologics, Inc. Common Stock are outstanding?
Theriva Biologics, Inc. Common Stock has 2.78M shares outstanding.